HPV and HPV Vaccine
A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Viral Immunology, Vaccines, and Antivirals".
Deadline for manuscript submissions: closed (31 May 2021) | Viewed by 57742
Special Issue Editor
Special Issue Information
Dear Colleagues,
Human papillomaviruses (HPVs) are double-stranded DNA viruses with an 8 kb genome. In 2008, Harald zur Hausen was awarded the Nobel Prize ‘for his discovery of human papillomaviruses causing cervical cancer’. There are over 100 types of HPV, of which 13 are considered to be carcinogenic. Of those types, HPV 16 and 18 account for the greatest proportion of cases of cervical cancer, and HPV 16 is associated with 90% of HPV+ head and neck cancers. In addition, members of the beta-papillomaviruses are associated with cutaneous squamous cell carcinoma (cSCC) in patients with epidermodysplasia verruciformis, and may contribute to UV-induced cSCC. Several virus-like particle vaccines have been developed for HPV, including, more recently, a nonavalent vaccine. These vaccines have high prophylactic efficacy.
In this Special Issue, we wish to explore current research in HPV and HPV vaccines. Topics of interest include, but are not limited to:
- the role of human papillomaviruses in cancer (including head and neck and skin cancer);
- the immune response to HPV, including protective immunity;
- animal papillomavirus studies that inform HPV immunity;
- elucidation of the mechanisms of regulation of host immunity by human papillomavirus; and
- HPV vaccines, including therapeutic vaccines targeting HPV.
Dr. Merilyn Hibma
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- human papillomavirus
- vaccine
- oncogenesis
- immune evasion
- immune response
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.